The current SMA diagnosis consensus and guidelines primarily focus on exon 7 deletion but do not include other exons, and the SMN1 gene can only be distinguished from SMN2 when some mutation is suspected to be carried by the patient. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.